Abstract
Paliperidone Palmitate is a long-acting intramuscular atypical antipsychotic drug indicated for the acute maintenance treatment of schizophrenia in adults. Its mechanism of action, like all other atypical agents, is attributed to the antagonism of brain dopamine D2 and serotonin 5-HT2A receptors. The pharmacodynamics, pharmacokinetics, and metabolism of paliperidone palmitate are reviewed. Current studies for clinical efficacy of paliperidone palmitate for both acute and maintenance treatment and adherence in adults with schizophrenia are discussed. Studies for safety and tolerability are also reviewed.
Keywords: Atypical Antipsychotics, Nonadherence, Schizophrenia, Paliperidone Palmitate, Long-acting Injectable, clinical efficacy, olanzapine, ziprasidone, risperidone, quetiapine
Reviews on Recent Clinical Trials
Title: Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia
Volume: 7 Issue: 1
Author(s): Elizabeth Gilday and Henry A. Nasrallah
Affiliation:
Keywords: Atypical Antipsychotics, Nonadherence, Schizophrenia, Paliperidone Palmitate, Long-acting Injectable, clinical efficacy, olanzapine, ziprasidone, risperidone, quetiapine
Abstract: Paliperidone Palmitate is a long-acting intramuscular atypical antipsychotic drug indicated for the acute maintenance treatment of schizophrenia in adults. Its mechanism of action, like all other atypical agents, is attributed to the antagonism of brain dopamine D2 and serotonin 5-HT2A receptors. The pharmacodynamics, pharmacokinetics, and metabolism of paliperidone palmitate are reviewed. Current studies for clinical efficacy of paliperidone palmitate for both acute and maintenance treatment and adherence in adults with schizophrenia are discussed. Studies for safety and tolerability are also reviewed.
Export Options
About this article
Cite this article as:
Gilday Elizabeth and A. Nasrallah Henry, Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia, Reviews on Recent Clinical Trials 2012; 7 (1) . https://dx.doi.org/10.2174/157488712799363307
DOI https://dx.doi.org/10.2174/157488712799363307 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design Multidrug Transporters as Drug Targets
Current Drug Targets Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure- Activity Relationships of a Neuroprotective Peptide
Current Medicinal Chemistry Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Current Management and Treatment of Cerebral Vasospasm Complicating SAH
CNS & Neurological Disorders - Drug Targets Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology Nitrergic Modulation of Gastrointestinal Function During Early Endotoxemia
Current Pharmaceutical Design Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Pharmacokinetics of Drugs in Neonates: Pattern Recognition Beyond Compound Specific Observations
Current Pharmaceutical Design Genomics of Addiction
Current Psychiatry Reviews Subclinical Vitamin B12 Deficiency and Heart Rate Variability Across Life Cycle
Current Aging Science Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Relaxin as a Cardiovascular Drug: A Promise Kept
Current Drug Safety Indications for Non-Invasive Ventilation in Respiratory Failure
Reviews on Recent Clinical Trials Pharmacological and Toxicological Profile of Harmane-β-Carboline Alkaloid: Friend or Foe
Current Drug Metabolism